James Pike, DO
Pulmonary Disease · Indianapolis, INNPI 1366443400
Payments from drug & device makers
Across 152 payments — averaging $32.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$891
- GSK$810
- Sunovion Pharmaceuticals Inc.$714
- Sumitomo Pharma America, Inc.$345
- Astellas Pharma US Inc$345
- Sanofi$344
- plus $2K from 13 others
What the payments were for
- Food & beverage$4,39088%
- Education$57212%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $891 |
| GSK | 21 | $810 |
| Sunovion Pharmaceuticals Inc. | 61 | $714 |
| Sumitomo Pharma America, Inc. | 9 | $345 |
| Astellas Pharma US Inc | 4 | $345 |
| Sanofi | 3 | $344 |
| Boehringer Ingelheim | 3 | $294 |
| Regeneron Healthcare Solutions, Inc. | 3 | $248 |
| Novo Nordisk | 8 | $155 |
| Amarin Pharma, Inc. | 7 | $151 |
| Ferring Pharmaceuticals Inc. | 6 | $141 |
| Genentech USA, Inc. | 3 | $134 |
| Novartis | 1 | $125 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $110 |
| Sanofi-aventis U.S. LLC | 2 | $70 |
| Mylan Specialty L.p. | 2 | $26 |
| E.r. Squibb & Sons, L.L.C. | 2 | $25 |
| Lilly USA, LLC | 1 | $21 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,961 in reported general payments places this provider in the 60th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,225 | $385,643 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 241 | $161,338 |
| Invega SustennaPaliperidone Palmitate | 39 | $133,633 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 11 | $116,976 |
| TrulicityDulaglutide | 123 | $106,584 |
| XareltoRivaroxaban | 298 | $90,981 |
| JardianceEmpagliflozin | 265 | $86,313 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 16 | $72,109 |
| RebifInterferon Beta-1a/Albumin | 20 | $71,898 |
| Breo ElliptaFluticasone/Vilanterol | 134 | $63,534 |
| XifaxanRifaximin | 19 | $59,856 |
| NuedextaDextromethorphan Hbr/Quinidine | 73 | $49,489 |
| SantylCollagenase Clostridium Hist. | 52 | $49,210 |
| OzempicSemaglutide | 45 | $46,429 |
| MyrbetriqMirabegron | 156 | $43,262 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $810 | $249,577483 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto, Procrit | $14 | $244,021371 claims |
| Boehringer IngelheimJardiance, Tradjenta | $294 | $127,840417 claims |
| Lilly USA, LLCTrulicity | $21 | $106,584123 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $110 | $59,85619 claims |
| Novo NordiskOzempic | $155 | $46,42945 claims |
| Astellas Pharma US IncMyrbetriq | $345 | $43,262156 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $714 | $38,44151 claims |
| NovartisEntresto | $125 | $18,05155 claims |
| AstraZenecaBreztri Aerosphere | $891 | $16,55227 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $345 | $14,17357 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Indianapolis
- Cynthia BrownIndianapolis$7.3M
- Roberto MachadoIndianapolis$219K
- Michael DuncanIndianapolis$146K
- Gary ZalogaIndianapolis$79K
- Abboud KawakIndianapolis$68K
- Ryan LogueIndianapolis$30K
- George RubeizIndianapolis$24K
- Clare ProhaskaIndianapolis$20K
- Rajat NarangIndianapolis$17K
- Marcus TielkerIndianapolis$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.